The Immunomonitoring Laboratory (IML) is a centralized immune monitoring facility that facilitates the translation of basic immune system research findings into the cancer immunotherapy arena, to support ongoing and new clinical cancer immunotherapy trials and to develop novel mechanistic insights into human immune system-cancer interactions. IML provides the means to monitor developing immune responses to new therapies in animal models of cancer treatment; to elucidate novel treatment strategies; or develop unique processes to evaluate treatment outcomes in translational studies. This shared resource provides the infrastructure and expertise to advance cancer immunotherapy outcomes.
The IML provides the structure, instrumentation and expertise to monitor the impact of specific immunotherapies on human and mouse immunologic profiles, interrogate mechanisms and pathways related to treatment protocols and advance the conceptual basis for targeted treatment strategies. Primary Goals
- To conduct assays and provide expertise to support efforts in the areas of human and mouse immunology and immunotherapy (bench to bedside).
- To explore new basic mechanisms derived from analysis of immune mediated diseases and immunotherapy (bedside to bench).
- To synergize with other Washington University Centers and Programs to investigate novel roles of immunity in disease processes.
- To harmonize assay procedures across Immunomonitoring shared resources.
Service available to All entities, including for-profit organizations.
Priority service for Specific groups, centers or departments – see Additional Information for details.
- Produce custom human and murine MHC I tetramers
- Produce custom human and murine MHC II tetramers
- Conjugate mAbs and tetramers with metal-containing polymer tags or fluorophores
- Provide single and multiple cytokine analyses from serum, plasma, cell culture supernatants or other fluids
- Perform lymphocyte functional assays
- Promote identification of new biomarkers for translational research
- Sample analysis by means of mass cytometry (CyTOF2/Helios) and flow cytometry (BD LSRFortessa X-20):
- Immunophenotyping, intracellular cytokine analysis, signaling profiling of murine and human samples;
- Consultations on CyTOF and flow cytometry panel design and analysis;
- CyTOF reagent bank: metal conjugated antibodies, barcoding reagents, antibody labeling kits for CyTOF; and
- Enterprise Cytobank platform subscription, a cloud-based storage and analysis solution optimized for high parameter workflows
- Provide tetramer staining and instrumentation support for Immunoassay laboratory
- Multiplex analysis using MSD or Luminex platforms
- Multiplex spatial imaging using Akoya PhenoCycler-Fusion (formerly CODEX) instrumentation
- Imaging Mass Cytometry using Hyperion
- Tissue processing for nucleic acids
- Processing of leukapheresis samples and blood processing
- The IML is equipped with three (3) state-of-the-art CyTOF2/Helios (Fluidigm) mass cytometers.
- The BD LSRFortessa X-20 flow cytometry analyzer is configured with 5 lasers and is able to detect up to 20 parameters simultaneously.
- Tetramer Production AKTA Pure FPLC.
- Luminex FLEXMAP 3D platform is capable of multi-analyte screening of samples using flow cytometry to detect analytes captured on polystyrene or magnetic beads.
- Meso Scale Discovery QuickPlex-120 technology offers the following advantages: High sensitivity and broad dynamic range, Flexibility, Clean Signals, Time- and Cost-Effective Processing and Consistent Results
- CTL Immunospot S6 ELISPOT provides a single-cell secretory footprint in the form of a colored spot that is scanned and counted for statistical significance.
- BioTek Synergy H1 Plate Reader Synergy™ H1 is a flexible monochromator-based multi-mode microplate reader.
- Hyperion imaging mass cytometer
- Akoya PhenoCycler-Fusion (formerly CODEX)
Please contact this core directly for pricing information.
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center (SCC)
Rheumatic Diseases Research Resource-based Center
Bursky Center for Human Immunology and Immunotherapy Programs (CHiiPs)